Purpose Life Sciences, Author at Purpose Life Sciences

The TOGETHER Trial consists of 22 sites across Brazil, where patients are being treated with a range of potential new COVID-19 therapeutic agents.

Blog

TOGETHER Trial – An Overview of the Award-Winning Trial of the Year

The TOGETHER trial is the result of a partnership between health researchers in Brazil and Canada. As the result of the COVID-19 pandemic and the serious implications for people living in low and medium-income countries, a partnership was rapidly formed to find affordable and effective treatments from existing medications already…

Purpose Life SciencesMay 8, 2023

Long-acting antiretrovirals and HIV treatment adherence

Publications

The importance of appropriate selection of clinical endpoints in outpatient COVID-19 clinical trials

Intramuscular injection of long-acting cabotegravir and rilpivirine is a novel, long-acting antiretroviral therapy (ART) combination approved for use as a fully suppressive regimen for people living with HIV.

Purpose Life SciencesApril 23, 2023

United States Senate Committee on Foreign Relations

News

Platform Life Sciences Executive Chairperson Testifies to the US Senate with Elton John

Mark Dybul, MD, the Executive Chairperson of Purpose Life Sciences, was one of only two expert witnesses along with Sir Elton John to testify before the Senate Foreign Relations Committee (SFRC) regarding the legislative renewal of the US President’s Emergency Plan for AIDS Relief (PEPFAR), the largest international health initiative…

Purpose Life SciencesApril 19, 2023

Publications

The effect of group support psychotherapy on adherence to anti-retroviral therapy and viral suppression among HIV positive young people: Study protocol for a pilot randomized controlled trial

Several studies have demonstrated an association between psychological risk factors and HIV disease progression. However, there is limited information on the use of psychological interventions to improve HIV treatment outcomes in young people living with HIV.

Purpose Life SciencesApril 5, 2023

Pegylated Interferon Lambda for Covid-19. Reply

Publications

Early Treatment with Pegylated Interferon Lambda for Covid-19

The efficacy of a single dose of pegylated interferon lambda in preventing clinical events among outpatients with acute symptomatic coronavirus disease 2019 (Covid-19) is unclear.

Purpose Life SciencesFebruary 10, 2023

News

Rwanda FDA approves Purpose Life Sciences and GreenLight Biosciences to launch a Phase I clinical trial in Rwanda for mRNA COVID-19 vaccine

Purpose Life Sciences, a high impact Clinical Research Organization, with the mission to modernize clinical trials on a global scale, has signed a key agreement with GreenLight Biosciences to support their Phase I clinical trial, GLB-003, for a novel mRNA vaccine against COVID-19 in Rwanda – that today has been…

Purpose Life SciencesFebruary 2, 2023

Publications

Estimating HIV Incidence In Sub-Saharan Africa

Over the past 3 years, the COVID-19 pandemic has affected health systems in sub-Saharan Africa that were already highly burdened by other infectious diseases such as HIV. Although substantial progress has been made in reducing new HIV infections globally, Africa is still disproportionately affected, accounting for two-thirds of all people…

Purpose Life SciencesJanuary 23, 2023

Publications

Advancing Detection And Response Capacities For Emerging And Re-Emerging Pathogens In Africa

Recurrent disease outbreaks caused by a range of emerging and resurging pathogens over the past decade reveal major gaps in public health preparedness, detection, and response systems in Africa. Underlying causes of recurrent disease outbreaks include inadequacies in the detection of new infectious disease outbreaks in the community, rapid pathogen…

Purpose Life SciencesDecember 21, 2022

Publications

Advancing Pathogen Detection and Tracking in Africa

Recurrent disease outbreaks caused by a range of emerging and resurging pathogens over the past decade reveal major gaps in public health preparedness, detection, and response systems in Africa.

Purpose Life SciencesDecember 20, 2022

Publications

Resilient clinical trial infrastructure in response to the COVID-19 pandemic

In 2020, clinical trial researchers developed protocols to evaluate the safety and effectiveness of potential treatments for COVID-19. Despite more than 3,000 trials registered, few have generated findings, with the exception of smaller randomized controlled trials.

Purpose Life SciencesSeptember 22, 2022

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Purpose Life Sciences

Cookie Policy